Skip to main navigation

Skip to Content

Home
About Us
Clinical Pipeline & Technology
- ANA001
- Gemcabene
- NB-01
- NB-02
Investors & News
Contact Us

Press Releases

Keyword Search

Year

Nov 08, 2022

NEUROBO ANNOUNCES CLOSING OF $32.3 MILLION UNDERWRITTEN PUBLIC OFFERING INCLUDING FULL EXERCISE OF OVERALLOTMENT OPTION AND CONCURRENT PRIVATE PLACEMENT

Nov 04, 2022

NEUROBO ANNOUNCES PRICING OF $30 MILLION UNDERWRITTEN PUBLIC OFFERING AND CONCURRENT PRIVATE PLACEMENT

Sep 29, 2022

NeuroBo Pharmaceuticals, Inc. Compliant with All Applicable Nasdaq Listing Criteria

Sep 15, 2022

NeuroBo Pharmaceuticals, Inc. and Dong-A ST Co. Ltd. Announce Strategic Collaboration to License and Develop Portfolio of Dong-A's Cardio-Metabolic Therapies

Sep 12, 2022

NeuroBo Pharmaceuticals Announces Reverse Stock Split

May 06, 2022

NeuroBo Pharmaceuticals, Inc. Expands Management Team with the Appointment of Matthew Bardin, PharmD, BCPS as Senior Vice President Operations

Apr 01, 2022

NeuroBo Pharmaceuticals Reports Full Year 2021 Financial Results

Mar 15, 2022

NeuroBo Pharmaceuticals, Inc. Expands Scientific Advisory Board with Appointment of Danamarie Belpulsi, M.D.

Jan 28, 2022

NeuroBo Pharmaceuticals, Inc. Appoints D. Gordon Strickland to its Board of Directors

Print

RSS Feeds

E-mail Alerts

IR Contacts

LinkedIn
Contact Us
Terms of Use
Privacy Policy

©2022 NeuroBo Pharmaceuticals, Inc.